Erratum to: Glycated albumin as a useful clinical biomarker for glycemic variability in type 1 diabetes assessed by continuous glucose monitoring

Abstract

Listen

Translate article

This study was conducted to evaluate HbA1c and GA as clinical markers for glycemic variability under normal daily living conditions, not in a hospital setting, in patients with type 1 diabetes by continuous glucose monitoring (CGM). Twenty-one outpatients with type 1 diabetes (age 47.2 ± 16.6 years, with a mean duration of diabetes of 11.1 ± 7.0 years) underwent up to 72 h of the CGM. We analyzed the correlation between ten parameters [mean glucose, area under the curve (AUC) at 180/70 mg/dl, %High/Low, SD, J-index, %CV, high blood glucose index (HBGI)/low blood glucose index (LBGI), M-value, mean amplitude of glycemic excursions (MAGE) and mean of daily differences (MODD)] and the levels of glycemic markers (HbA1c, GA and the GA/HbA1c ratio). The average levels of HbA1c, GA and the GA/HbA1c ratio were 7.9 ± 0.9 %, 25.6 ± 4.4 % and 3.4 ± 0.5, respectively. The Pearson univariate correlation analysis showed that both the levels of HbA1c and GA, but not the GA/HbA1c ratio, were closely related to the CGM-measured mean glucose, AUC at 180, %High, HBGI and the M value. The GA levels also positively correlated with the SD (R = 0.46, P = 0.035), J-index (R = 0.67, P = 3.5 × 10−3) and MAGE (R = 0.45, P = 0.042), while the HbA1c levels did not. In addition, the GA/HbA1c ratio correlated significantly with the glycemic variability, SD (R = 0.58, P = 5.7 × 10−3), J-index (R = 0.45, P = 0.039), M-value (R = 0.46, P = 0.035) and MAGE (R = 0.60, P = 4.3 × 10−3). In conclusion, GA and the GA/HbA1c ratio could therefore be useful clinical markers for the blood glucose level and glycemic variability in patients with type 1 diabetes.